About Us

Home / About Us / Our Team / 
Thomas Lackner

Thomas Lackner


Thomas Lackner joined as our Senior Vice President, Head of Europe in February 2019. Thomas is a global biopharma leader with over 25 years of commercial experience. Prior to joining Apellis, Mr. Lackner was responsible for building the commercial organization for Prothena Biosciences in Europe for their first global launch in a hematologic rare disease (AL amyloidosis). Thomas was also responsible for the development of Prothena’s global commercial strategy.

Prior to that, Thomas finished a 15-year long career at Biogen as Vice President, Managing Director Germany (including Austria and Switzerland), their second most important market; having previously held P&L responsibilities for the Nordic, Benelux and Iberian countries in Europe, as well as for Canada.

Thomas’ launch experience also covers full accountability for the global launch of FampyraTM in multiple sclerosis together with Acorda Therapeutics where he also chaired the Joint Commercial Committee.

At Biogen he first worked on taking back businesses successfully from distributors to start-up Biogen’s own distribution operations in Eastern Europe.

Thomas began his career in pharmaceuticals marketing and sales in Austria with Eli Lilly, before moving to Wyeth (subsequently acquired by Pfizer) where he launched EnbrelTM (rheumatoid arthritis) and ReFactoTM (hemophilia) before becoming their General Manager for Austria.

Thomas obtained his MBA from Texas A&M University in College Station, Texas, as well as a MS in Business Administration from Johannes Kepler University in Linz, Austria.

Apellis logo
© Apellis Pharmaceuticals 2019.